| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 447.70 | 1.1% |
| Total Income | 451.30 | 0.4% |
| Expenditure | 427.50 | 0.2% |
| PBT | 23.80 | 4.0% |
| Net Profit | 17.20 | 6.0% |
| OPM | -7.08% | 1.32pp |
| NPM | 3.81% | 0.23pp |
| EPS | 1.39 | 6.1% |
Hikal Ltd. Reports Q3 FY25 Revenue of Rs. 448 Crore, EBITDA of Rs. 72 Crore, and 11% EBITDA Growth
04 Feb 2025 · 4 Feb 2025, 09:34 pm
Summary
Hikal Ltd., a leading global life sciences company, announced its unaudited financial results for the quarter and nine months ended 31st December 2024. The company's revenue for Q3 FY25 stood at Rs. 448 crore, with an EBITDA of Rs. 72 crore, marking an 11% EBITDA growth on a YoY basis. The Board of Directors has recommended an interim dividend of 30%. The pharmaceutical business is capitalizing on the China+1 strategy, and the crop protection industry is showing signs of stabilization.
Key Highlights
- 1
Q3FY25 consolidated Revenue recorded at Rs 448 Crore
- 2
EBITDA Q3FY25 stood at Rs. 72 crore, a 11% EBITDA growth on YoY basis
- 3
Pharmaceutical business is capitalizing on China+1 strategy
- 4
Crop Protection industry has started to exhibit signs of stabilization
- 5
Board of Directors has recommended an interim dividend of 30%
- 6
Q3 FY25 EBITDA Margin improved on YoY basis
- 7
PAT stood at Rs. 17 crore
- 8
Hikal’s long term credit rating is maintained at A+ by ICRA Mumbai
Management Comments
Jai Hiremath
Executive Chairman, Hikal Ltd.
In the global pharmaceutical industry, we are witnessing positive momentum led by CDMO opportunities while the crop protection industry is showing signs of stabilization. In Q3 FY25, our revenue amounted to Rs. 448 Cr, with an EBITDA of Rs. 72 Cr, a 11% EBITDA growth on YoY basis. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA of Rs. 205 Cr, a growth of 3% and 19% respectively. The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped us to improve our margin profile. Our focused business initiatives have resulted in increased operating cash flows of Rs. 102 Cr YoY on 9 months basis. Our Board of Directors has recommended an interim dividend of Rs. 0.60 per share (30%). In Q3 FY25, our pharmaceutical revenue stood at Rs. 293 Cr with EBIT margin of 11.4%, an increase of 449 bps, on a YoY basis. Our CDMO business continues to see an increasing flow of new enquiries as a result of the China+1 strategy by global pharmaceutical companies. We are confident to deliver profitable growth based on a healthy pipeline of projects in various phases of the life cycle. Our API segment continues to gain traction driven by improved geographical penetration and an increased customer base. In Q3 FY25, our crop protection revenue stood at Rs. 154 Cr, with an EBIT margin of 9%. The sector has started to exhibit signs of stabilization, predominantly driven by domestic markets. We are seeing a marginal recovery in volumes, although global market prices for actives continue to remain low. In our animal health segment, the project under our long-term agreement with an innovator customer is progressing well and we will conclude the validation over the next two quarters. Our products are undergoing registration and ultimately launching these products in global markets. Under our strategic transformation initiative - Pinnacle, we continue to make substantial strides toward achieving sustainable growth across our businesses. We are witnessing early signs of success in development of new capabilities and differentiated technology platform as well as customers base expansion. We have successfully integrated sustainable practices into our ESG initiatives.”
Informational and educational content only. Not investment advice.